Search results for: NICE
Filter search results
Meindert Boysen
13 March 2025
…was director of the health technology evaluation programmes at the National Institute for Health and Care Excellence (NICE), and deputy Chief Executive Officer. In his role as director, Meindert was…
Around the World in HTAs: Canada – Autonomous yet Collaborative
9 April 2025
…used by England’s National Institute for Health and Care Excellence (NICE). CDA-AMC’s processes also differ from NICE’s in terms of committees’ explicit consideration of feasibility (especially infrastructure needs and affordability)…
How long are patients WAITing for new treatments?
2 July 2026
…the rate, extent, and speed of availability requires careful interpretation. England illustrates the point: the accessibility date for a NICE-approved medicine is governed by the NHS funding directive, which gives local…
OHE in the BMJ: Reforming the Cancer Drug Fund, and Reviving the PROMs Programme
10 December 2014
…for prioritising access to it “will continue to undermine NICE, duplicate effort, and distort allocation of NHS resources while failing to support the development of cost effective drugs from which…
OHE at ISPOR Philadelphia: Presentations and Posters
4 June 2015
…large prevalence diseases? Lessons from hepatitis C – Adrian Towse’s slides Early access to medicines: What is in it for payers? – Adrian Towse’s slides An Analysis of NICE ‘Recommended…
OHE Lunchtime Seminar on 14 December 2015: From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers
13 November 2015
…decision-making criteria employed by health technology assessment (HTA) agencies differs between countries. Specifically, while the National Institute for Health and Care Excellence (NICE), the Australian Pharmaceutical Benefits Advisory Committee (PBAC)…
OHE and ABPI Webinar: New EQ-5D-5L value sets for England and the UK and Implications for HTA
11 July 2016
…instrument recommended by the National Institute for Health and Care Excellence (NICE) for use in estimating Quality Adjusted Life Years (QALYs) in cost effectiveness analysis. It is accompanied by a…
OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
26 October 2016
…Excellence (NICE) and were not routinely available within the NHS in England. After a consultation process, it was agreed that from July 2016, NICE will appraise all new licenced cancer…
25 Years of the Cost Effectiveness Acceptability Curve
30 December 2019
…25 years. She noted that “the substantial impact of the paper is also clear from its inclusion in methods guidelines, including NICE’s methods for technology assessment and in the recommendations…